Pharmaceuticals, Healthcare, and Research by Bristol Myers Squibb

  • Ashutosh Sureka
  • 17.06.2026
Bristol-Myers Squibb stock trades lower with weekly decline intensifying amid bearish momentum
Bristol-Myers Squibb opened its NYNJ World Cup 26 Jersey Fan Hub, featuring mascot Squibby, in New Jersey.The company stated that it is standing shoulder to shoulder with communities to advance ...
  • Parshwa Turakhiya
  • 10.06.2026
Bristol-Myers Squibb stock closes near weekly low amid persistent short-term pressure
Bristol-Myers Squibb said its commitment to patient outcomes continues as the world prepares for the 2026 FIFA World Cup.The company promoted its #BMSWontLose campaign in a recent tweet. ...
  • Oleg Tkachenko
  • 29.03.2026
Bristol-Myers Squibb stock price forecast: short-term resistance holds as BMY slips 1.5%
Bristol-Myers Squibb is presenting the full Phase 3 SCOUT-HCM trial results at ACC26. The company says the data showcase a potential treatment option for adolescents with symptomatic obstructive ...
  • Ezequiel Gomes
  • 28.03.2026
Neuroscience data release drives Bristol-Myers Squibb stock lower 1.50%
Bristol-Myers Squibb is presenting abstracts from its neuroscience portfolio at this year’s SIRS2026.The company’s presentation includes new data related to schizophrenia. Details are ...
  • Hanna Syniavska
  • 27.03.2026
Bristol-Myers Squibb stock price forecast: consolidation likely as BMY eyes upper range resistance
Bristol-Myers Squibb presented new clinical and real-world data in symptomatic obstructive hypertrophic cardiomyopathy at ACC26.The company stated these data build on its research. Results show ...
  • Ashutosh Sureka
  • 20.03.2026
Bristol Myers Squibb wins U.S. FDA and European Commission approval for immunotherapy Hodgkin lymphoma treatment
Bristol Myers Squibb has received approval from both the U.S. FDA and the European Commission for its immunotherapy-based treatment combinations targeting classical Hodgkin lymphoma in certain ...
  • Elena Nikulina
  • 17.02.2026
Bristol Myers Squibb gains FDA nod for multiple myeloma drug
Bristol Myers Squibb received a significant boost as the U.S. FDA accepted its New Drug Application for an investigational treatment for adult patients with relapsed or refractory multiple ...
  • Eugene Komchuk
  • 03.02.2026
Bristol Myers Squibb launches clinician education on FXIa research
Bristol Myers Squibb has announced the launch of a new educational campaign aimed at clinicians. The initiative focuses on underscoring the unmet needs in cardiovascular and thromboembolic care ...